Semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), works through mechanisms that overlap with the physiological changes produced by sleeve gastrectomy
The peptide's inclusion reflects theoretical advantage rather than demonstrated efficacy in humans
Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials
GI Side Effect Overlap: Nausea, Reflux, and Bloating Both Wegovy and the conditions PPIs treat involve the upper gastrointestinal tract
A dramatic improvement in metabolic markers without a corresponding explanation (new diet, exercise program, other medication changes) may prompt questions
It does this by binding to the melanocortin 1 receptor (MC1R)